| Mark Reardon, MD | |
|
2213 Cherry St, Toledo, OH 43608-2603 | |
| (419) 251-4364 | |
| Not Available |
| Full Name | Mark Reardon |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
| Location | 2213 Cherry St, Toledo, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497733935 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0500X | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine | 35-055423 (Ohio) | Primary |
| Entity Name | Mount Carmel Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457617235 PECOS PAC ID: 6709793367 Enrollment ID: O20120727000563 |
News Archive
Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.
Nanotherapeutics, Inc., today announced that it has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major).
Contrary to popular belief among recreational drug users, mephedrone has several important differences when compared with MDMA, commonly known as ecstasy. These differences mean that mephedrone could leave a user with acute withdrawal symptoms and indicate that it may have a higher potential for developing dependence than MDMA according to a study published in British Journal of Pharmacology.
A study led by researchers at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health has identified a constellation of metabolites related to myalgic encephalomyelitis/chronic fatigue syndrome.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Reardon, MD 7536 Rymoor Ct, Sylvania, OH 43560-1889 Ph: () - | Mark Reardon, MD 2213 Cherry St, Toledo, OH 43608-2603 Ph: (419) 251-4364 |
News Archive
Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.
Nanotherapeutics, Inc., today announced that it has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major).
Contrary to popular belief among recreational drug users, mephedrone has several important differences when compared with MDMA, commonly known as ecstasy. These differences mean that mephedrone could leave a user with acute withdrawal symptoms and indicate that it may have a higher potential for developing dependence than MDMA according to a study published in British Journal of Pharmacology.
A study led by researchers at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health has identified a constellation of metabolites related to myalgic encephalomyelitis/chronic fatigue syndrome.
› Verified 9 days ago
Dr. Victor S Roth, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1455 W Alexis Rd, Gm Powertrain Medical Department, Toledo, OH 43612 Phone: 734-470-4244 | |
Dr. Michael Riethmiller, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2213 Cherry St, Toledo, OH 43608 Phone: 419-251-3679 | |
Dr. Harvey Andrew Popovich, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2213 Cherry St, Toledo, OH 43608 Phone: 419-251-2475 Fax: 419-251-0335 | |
Dr. John M. Barton, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2213 Cherry St, Toledo, OH 43608 Phone: 419-251-4634 | |
Mary Joan Apodaca, RN Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 635 N Erie St, Toledo, OH 43604 Phone: 419-213-4121 Fax: 419-213-4196 | |
Bret Edward Lindstrom, D.O Preventive Medicine Medicare: Medicare Enrolled Practice Location: 2142 N Cove Blvd, Toledo, OH 43606 Phone: 419-291-4000 |